Bukwang Pharmaceutical IND부광약품
003000 · KOSPI · ₩003000 · 부광약품
₩3,750▼ ₩5 (0.13%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Oct 23, 2026Open on DART
Predicted impact: Medium
Preliminary consolidated results for company with 215B won revenue; no figures given to judge surprise.
- Investor relations (IR) event기업설명회(IR)개최(안내공시)Oct 15, 2026Open on DART
Predicted impact: Low· Actual: −1.0% vs sector, volume 0.5× normal (5 trading days)
- Decision Regarding Rehabilitation and Bankruptcy Procedures of Invested Company출자법인회생절차및파산관련결정Aug 31, 2026Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Aug 28, 2026Open on DART
- Acquisition of property, plant and equipment유형자산취득결정Aug 26, 2026Open on DART
- Bankruptcy Rehabilitation Procedures and Related Bankruptcy Application of Invested Company출자법인회생절차및파산관련신청Aug 14, 2026Open on DART
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation Bodies지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항Aug 13, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 13, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Jul 21, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최(안내공시)Jul 15, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 ((라투다정의 추가 적응증 3상 임상시험계획(IND) 승인)Jun 2, 2026Open on DART
- Disclosure of Corporate Governance Report기업지배구조보고서공시Jun 1, 2026Open on DART
- Disclosure of Large Business Group Status [Annual Disclosure and Q1 Use (Individual Companies)]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]May 29, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 14, 2026Open on DART
- Amended: Acquisition of shares in another company[기재정정]타법인주식및출자증권취득결정May 13, 2026Open on DART
- Acquisition of shares in another company타법인주식및출자증권취득결정Apr 27, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Apr 21, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최(안내공시)Apr 15, 2026Open on DART
- Corporate value-up plan기업가치제고계획(자율공시)Mar 24, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 24, 2026Open on DART
- Audit report submitted감사보고서제출Mar 16, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 16, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 9, 2026Open on DART
- Amended: Major sales or supply contract[기재정정]단일판매ㆍ공급계약체결Feb 27, 2026Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Feb 27, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 23, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Feb 23, 2026Open on DART
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation Bodies지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항Feb 13, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경Feb 9, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최(안내공시)Feb 2, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Jan 5, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Dec 22, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Dec 17, 2025Open on DART
- Shareholder Register Closure for Cash/Stock Dividend (Record Date) Decision현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정Dec 16, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Nov 28, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최(안내공시)Nov 12, 2025Open on DART
- Shareholder Register Closure for Cash/Stock Dividend (Record Date) Decision현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정Oct 21, 2025Open on DART
- Cash dividend decision현금ㆍ현물배당결정Oct 21, 2025Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Oct 21, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최(안내공시)Oct 16, 2025Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Aug 29, 2025Open on DART
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation Bodies지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항Aug 14, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 24, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 24, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jul 24, 2025Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Jul 22, 2025Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Jul 21, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Bukwang Pharmaceutical IND / 부광약품 / 003000 / KRX:003000
Source: KRX statistical information